Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Butylscopolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 7/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.98 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.78 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.76 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.76 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylscopolamine SCHEMBL1650352 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29373202 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL25291 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2441812 | 1.00 | BLM (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL5028833 | 0.99 | BLM (0.98) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL16168163 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29643439 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL2446869 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL14672547 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 | |
| Butylscopolamine SCHEMBL29473416 | 0.99 | CHRM2 (1.00) | BLMPMP22LMNACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 635 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010096820-A1 | CONTROLLED RELEASE COMPOSITIONS COMPRISING ANTI-CHOLINERGIC DRUGS | EURAND, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008145733-A2 | NOVEL CHEMICAL COMPOUNDS, PRODUCTION THEREOF, AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2008-12-04 | — | — | WO | claimed |
| EP-1464300-B1 | Blood vessel-urethra stent | REFLOW GMBH (DE) | 2008-10-29 | — | — | EP | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-1464300-A1 | Blood vessel-urethra stent | Walter, Thomas (DE) | 2004-10-06 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| EP-1072260-A1 | Transdermal systems for the release of muscarinic receptor antagonists and use thereof for treatement of smooth muscle spasms in urology | Novosis Pharma AG (DE) | 2001-01-31 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0304730-B1 | MEDICAMENTS CONTAINING N-ALKYL SCOPOL AMINE SALT AND NITROGLYCERINE, METHOD FOR ITS PREPARATION AND ITS USE | G. Pohl-Boskamp GmbH & Co. Chemisch-pharmazeutische Fabrik (DE) | 1991-06-26 | — | — | EP | claimed |
| EP-0304730-A1 | Medicaments containing N-alkyl scopol amine salt and nitroglycerine, method for its preparation and its use | G. Pohl-Boskamp GmbH & Co. Chemisch-pharmazeutische Fabrik (DE) | 1989-03-01 | — | — | EP | claimed |
| US-4668684-A | Combination of flupirtin and anticholinergic acting spasmolytic | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | claimed |
| EP-4168092-B1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | BARD INC C R (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-4381303-A | 1,4,9,10-Tetrahydro-pyrazolo [4,3-]pyrido[-3,2-b][1,4]diazepin-10-ones | DR. KARL THOMAE GMBH (DE) | 1983-04-26 | — | — | US | disclosed |
| EP-0076515-A1 | Rapidly releasable microcapsules and method for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1983-04-13 | — | — | EP | disclosed |
| EP-0066774-A1 | 1,4,9,10-Tetrahydropyrazolo(4,3-e)pyrido(3,2-b)(1,4)diazepin-10-ones, process for their preparation and medicinal preparations containing them | Dr. Karl Thomae GmbH (DE) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | CHRM2 4475/4885CHRM1 4534/4885CHRM5 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.